Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes

American Heart Journal

Volumn 157, Issue 4, 2009, Pages

  Rao, Rajeev V ^a   Goodman, Shaun G ^a   Yan, Raymond T ^a   Spencer, Frederick A ^b   Fox, Keith A ^c   DeYoung, J Paul ^d   Rose, Barry ^e   Grondin, François R ^f   Gallo, Richard ^g   Gore, Joel M ^h   Yan, Andrew T ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d Department of Diagnostic Imaging   (Canada)

^e Health Sciences Centre St John's   (Canada)

^f Hotel Dieu de Levis Hospital   (Canada)

^g MONTREAL HEART INSTITUTE   (Canada)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPERFUSION; SCORING SYSTEM; ST SEGMENT ELEVATION;

EID: 63449093485     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.01.002     Document Type: Article

References (34)

1. ISIS-2 (SECOND INTERNATIONAL STUDY OF INFARCT SURVIVAL) COLLABORATIVE GROUP. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2 (1988) 349-360
2. Michelson A.D. P2Y12 antagonism: promises and challenges. Arterioscler Thromb Vasc Biol 28 (2008) s33-s38
3. Jennings L.K., and Saucedo J.F. Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. Curr Opin Cardiol 23 (2008) 302-308
4. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration
5. Antman E.M., Hand M., Armstrong P.W., et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 51 (2008) 210-247
6. Harrington R.A., Becker R.C., Cannon C.P., et al. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 6 Suppl (2008) 670S-707S
7. Steg P.G., Goldberg R.J., Gore J.M., et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol 90 (2002) 358-363
8. The GRACE Investigators. Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 141 (2001) 190-199
9. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
10. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
11. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
12. Granger C.B., Goldberg R.J., Dabbous O., et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 163 (2003) 2345-2353
13. University of Massachusetts Medical School-Centre for Outcomes Research. GRACE Risk Table. Available at:http://www.outcomes-umassmed.org/grace/grace_risk_table.cfmLast accessed February 9, 2009
14. Yan A.T., Jong P., Yan R.T., et al. Clinical trial-derived risk model may not generalize to real-world patients with acute coronary syndrome. Am Heart J 148 (2004) 1020-1027
15. Yan A.T., Yan R.T., Tan M., et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J 28 (2007) 1072-1078
16. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 358 (2001) 527-533
17. Gibson C.M., Murphy S.A., Pride Y.B., et al. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study. Am Heart J 155 (2008) 133-139
18. Szuk T., Gyongyosi M., Homorodi N., et al. Effect of timing of clopidogrel administration on 30-day clinical outcomes: 300-mg loading dose immediately after coronary stenting versus pretreatment 6 to 24 hours before stenting in a large unselected patient cohort. Am Heart J 153 (2007) 289-295
19. Rogers W.J., Canto J.G., Lambrew C.T., et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol 36 (2000) 2056-2063
20. Fox K.A., Goodman S.G., Anderson Jr. F.A., et al. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24 (2003) 1414-1424
21. Yan A.T., Yan R.T., Tan M., et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics and 1-year outcome. Am Heart J 154 (2007) 1108-1115
22. Heras M., Bueno H., Bardaji A., et al. Magnitude and consequences of undertreatment of high-risk patients with non-ST segment elevation acute coronary syndromes: insights from the DESCARTES Registry. Heart 92 (2006) 1571-1576
23. Eagle K.A., Nallamothu B.K., Mehta R.H., et al. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go. Eur Heart J 29 (2008) 609-617
24. Mehta R.H., Roe M.T., Chen A.Y., et al. Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. Arch Intern Med 166 (2006) 2027-2034
25. Tricoci P., Roe M.T., Mulgund J., et al. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 166 (2006) 806-811
26. Alexander D., Ou F.S., Roe M.T., et al. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE). Am Heart J 156 (2008) 606-612
27. McAlister F.A., Oreopoulos A., Norris C.M., et al. Exploring the treatment-risk paradox in coronary disease. Arch Intern Med 167 (2007) 1019-1025
28. Yan A.T., Yan R.T., Tan M., et al. Management patterns in relation to risk stratification among patients with non-ST elevation acute coronary syndromes. Arch Intern Med 167 (2007) 1009-1016
29. Fox K.A., Mehta S.R., Peters R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 110 (2004) 1202-1208
30. Mehta R.H., Chen A.Y., Pollack Jr. C.V., et al. Challenges in predicting the need for coronary artery bypass grafting at presentation in patients with non-ST-segment elevation acute coronary syndromes. Am J Cardiol 98 (2006) 624-627
31. Chew D.P., Mahaffey K.W., White H.D., et al. Coronary artery bypass surgery in patients with acute coronary syndromes is difficult to predict. Am Heart J 155 (2008) 841-847
32. Yusuf S., Mehta S.R., Zhao F., et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 107 (2003) 966-972
33. Eagle K.A., Lim M.J., Dabbous O.H., et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 291 (2004) 2727-2733
34. Budaj A., Yusuf S., Mehta S.R., et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation 106 (2002) 1622-1626